肺分支动脉留置导管内生物制剂灌注治疗晚期肺癌

Late Stage Lung Cancer Treated by Percutaneous Branched Pulmonary Artery Catheter Injected with Biological Preparations

探讨IL—2/LAK细胞在介入式局部应用中的抗肿瘤作用,寻求疗效确切、操作可行的晚期肺癌生物治疗的应用途径。我们对60例晚期肺癌随机分为治疗组对照1组和对照2组。治疗组采用经皮颈外静脉穿刺肺分支动脉插管留置、IL—2、LAK细胞及化疗药物联合滴注治疗;对照1组以相同生物制剂及化疗药物外周静脉应用;对照2组采用单纯静脉化疗。三组化疗药物剂量及疗程均相同。结果:三组有效率(CR+PR)分别为:治疗组53.3％,对照1组39.9％,对照2组33.3％。结论:IL—2、LAK细胞与化疗药物联合应用能起到抗肿瘤的协同作用。IL—2、LAK细胞介入式局部应用弥补了其在体内半衰期短的缺陷,使肿瘤靶组织获得大剂量免疫细胞成为可能,从而提高其抗肿瘤作用。

In this article, we discussed anti-tumor effect of Interleukin- I (IL-2) and Lymphokin - activated Killer (LAK) cells, as in local percutaneous irans-catheter intervention application , and intended to seek an application of biotherapy, of which having both definate therapeutic effect and feasible manipulation in late stage lung cancer. Altogether 60 cases of late stage lung cancer, randomized into 3 groups. In therapeutic group, we did percutaneous branched pulmonary artery catheter through external jugular artery, with IL - 2,LAK cells and other chemotherapy drugs injected into in combination. In controled group 2, we gave only the same chemotherapy through peripheral vein. The effective rates (CR-f-PR) were-.therapeutic group 53. 5% ,controlled group 1 39. 8% and controlled group 2 33. 3%. It had been shown that: 1. when IL -2 and LAK calls and other chemotherapy drugs were used in combination . there would be a synergistic action of anti-tumor effect. 2. the local percutaneous trans-catheter intervention application of IL - 2 and LAK cells made up for their short half-time in human body, and made it possible for target tumor tissue acquiring higher dosage of immunological cells, thus help promote their anti-tumor effect.